Emerging inhalation aerosol devices and strategies: Where are we headed?

Advanced Drug Delivery Reviews

Volumn 75, Issue , 2014, Pages 3-17

  Zhou, Qi Tony ^a   Tang, Patricia ^a   Leung, Sharon Shui Yee ^a   Chan, John Gar Yan ^a,b   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Computational modelling; Dry powder inhaler; Inhalation therapy; Nebuliser; Particle engineering; Patient adherence; Pressurised metered dose inhaler; Pulmonary drug delivery

Indexed keywords

AEROSOLS; ATOMIZERS; COMPUTER SOFTWARE PORTABILITY; CONTROLLED DRUG DELIVERY; RESPIRATORY THERAPY; TARGETED DRUG DELIVERY;

COMPUTATIONAL MODELLING; DRY POWDER INHALER; INHALATION THERAPY; METERED-DOSE INHALERS; NEBULISER; PARTICLE ENGINEERING; PATIENT ADHERENCE; PULMONARY DRUG DELIVERY;

DRUG DOSAGE;

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; AMIKACIN; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; AZTREONAM LYSINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; CORTICOSTEROID; CYCLOSPORIN A; FORMOTEROL FUMARATE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ILOPROST; INTERLEUKIN 2; LANINAMIVIR; LANINAMIVIR OCTANOATE; LEVOFLOXACIN; MONOCLONAL ANTIBODY; MUSCARINIC RECEPTOR BLOCKING AGENT; RIFAMPICIN; SIALIDASE INHIBITOR; TOBRAMYCIN; AEROSOL; RESPIRATORY TRACT AGENT;

ACCURACY; AEROSOL; ASTHMA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTATIONAL FLUID DYNAMICS; COMPUTER PROGRAM; DOSE RESPONSE; DRUG FORMULATION; DRUG MEGADOSE; DRY POWDER INHALER; EQUIPMENT DESIGN; FIBROSING ALVEOLITIS; GRAFT REJECTION; HUMAN; INFLUENZA; INHALATION SPACER; METERED DOSE INHALER; NEBULIZER; NONHUMAN; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; STRATEGIC PLANNING; TUBERCULOSIS; DRUG DELIVERY SYSTEM; LUNG DISEASES;

AEROSOLS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; RESPIRATORY SYSTEM AGENTS;

EID: 84908259448     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.03.006     Document Type: Review

References (194)

1. Knoch M., Keller M. The customised electronic nebuliser: A new category of liquid aerosol drug delivery systems. Expert Opin. Drug Deliv. 2005, 2:377-390.
2. Fischer A., Stegemann J., Scheuch G., Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur. J. Med. Res. 2009, 14:71-77.
3. Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst. Rev. 2013, 4:CD007639.
4. Rubin B.K. Pediatric aerosol therapy: new devices and new drugs. Respir. Care 2011, 56:1411-1423.
5. Dalby R., Spallek M., Voshaar T. A review of the development of Respimat® Soft Mist™ Inhaler. Int. J. Pharm. 2004, 283:1-9.
6. Cipolla D., Chan H.-K., Schuster J., Farina D. Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther. Deliv. 2010, 1:667-682.
7. Watts A.B., McConville J.T., Williams R.O. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev. Ind. Pharm. 2008, 34:913-922.
8. Arunthari V., Bruinsma R.S., Lee A.S., Johnson M.M. A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Respir. Care 2012, 57:1242-1247.
9. Leung K., Louca E., Coates A.L. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004, 126:1619-1627.
10. Rau J.L., Ari A., Restrepo R.D. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir. Care 2004, 49:174-179.
11. Kroneberg P., Zimlich W., Muellinger B., Wenker A., Scheuch G. Device output is not a predictor of lung dose. Drug Delivery to the Lung 19, Edinbugh, United Kingdom 2008.
12. Fleming J., Conway J., Majoral C., Tossici-Bolt L., Katz I., Caillibotte G., Perchet D., Pichelin M., Muellinger B., Martonen T., Kroneberg P., Apiou-Sbirlea G. The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:49-60.
13. Bakker E.M., Volpi S., Salonini E., van der Wiel-Kooij E.C., Sintnicolaas C.J.J.C.M., Hop W.C.J., Assael B.M., Merkus P.J.F.M., Tiddens H.A.W.M. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur. Respir. J. 2011, 38:1328-1335.
14. Moller W., Heimbeck I., Hofer T.P., Khadem Saba G., Neiswirth M., Frankenberger M., Ziegler-Heitbrock L. Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or the alveoli in man. PLoS One 2012, 7:e33505.
15. Kesser K.C., Geller D.E. New aerosol delivery devices for cystic fibrosis. Respir. Care 2009, 54:754-768.
16. Diaz K.T., Skaria S., Harris K., Solomita M., Lau S., Bauer K., Smaldone G.C., Condos R. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:79-87.
17. Martischnig A.M., Tichy A., Nikfardjam M., Heinz G., Lang I.M., Bonderman D. Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. J. Card. Fail. 2011, 17:813-818.
18. Goodman N., Morgan M., Nikander K., Hinch S., Coughlin S. Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 1):S61-S70.
19. Nikander K., Denyer J., Dodd M., Dyche T., Webb K., Weller P., Stableforth D. The Adaptive Aerosol Delivery system in a telehealth setting: patient acceptance, performance and feasibility. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:S21-S27.
20. Stein S.W., Sheth P., Hodson P.D., Myrdal P.B. Advances in metered dose inhaler technology: hardware development. AAPS PharmSciTech 2013, 1-13.
21. Melani A.S., Bonavia M., Cilenti V., Cinti C., Lodi M., Martucci P., Serra M., Scichilone N., Sestini P., Aliani M., Neri M. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2012, 105:930-938.
22. Fink J.B., Rubin B.K. Problems with inhaler use: a call for improved clinician and patient education. Respir. Care 2005, 50:1360-1375.
23. Gross G., Cohen R.M., Guy H. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. J. Asthma 2003, 40:487-495.
24. Worth H., Muir J.F., Pieters W.R. Comparison of hydrofluoroalkane-beclomethasone dipropionate autohaler (TM) with budesonide turbuhaler (TM) in asthma control. Respiration 2001, 68:517-526.
25. Zuyderhoudt K.F.M. Inhalers and Housing Caps for Inhalers 2012, (PCT/EP2011/006000).
26. Azouz W., Campbell J., Stephenson J., Saralaya D., Chrystyn H. Improved metered dose inhaler technique when a coordination cap is used. J. Aerosol Med. Pulm. Drug Deliv. 2013, (ahead of print). 10.1089/jamp.2012.1031.
27. Leach C.L., Colice G.L. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:355-361.
28. Mansfield L.E., Maynes R. A valved holding chamber does not decrease the bronchodilator activity of budesonide-formoterol combination metered dose inhaler. J. Asthma 2013, 50:71-74.
29. Crim C., Holmes M., Lee B., Cavanaugh R., Lincourt W. Evaluation of particle size distribution of albuterol sulfate hydrofluoroalkane administered via metered-dose inhaler with and without valved holding chambers. Ann. Allergy Asthma Immunol. 2005, 94:80-85.
30. Nagel M.W., Wiersema K.J., Bates S.L., Mitchell J.P. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. J. Aerosol Med. 2002, 15:427-433.
31. Ten Have W.H.O., De Berg N.J.V., Bindels P.J.E., Van Aalderen W.M.C., Van Der Palen J. Assessment of inhalation technique in children in general practice: increased risk of incorrect performance with new device. J. Asthma 2008, 45:67-71.
32. Newman S.P. Principles of metered-dose inhaler design. Respir. Care 2005, 50:1177-1190.
33. Oliveira R.F., Teixeira S.F.C.F., Silva L.F., Teixeira J.C.F., Antunes H. Development of new spacer device geometry: a CFD study (part I). Comput. Methods Biomech. Biomed. Eng. 2012, 15:825-833.
34. Goncalves T.M., Alhanout K., Nicolay A., Dubus J.C., de Santana D.P., Andrieu V. Comparative in vitro performance of three small-volume valved holding chambers with beclomethasone/formoterol pressurized metered dose inhaler. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:223-227.
35. US Food and Drug Administration Guidance for Industry. Integration of Dose-counting Mechanisms into MDI Drug Products 2003.
36. Weinstein C., Staudinger H., Scott I., Amar N.J., LaForce C. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir. Med. 2011, 105:979-988.
37. Wasserman R.L., Sheth K., Lincourt W.R., Locantore N.W., Rosenzweig J.C., Crim C. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc. 2006, 27:486-492.
38. Allsop P., Bainton M.C., Day S.A., Dickens C., Glenton D.J., Kelly S.G.D., Perkins R., Warby R.J. Metered Dose Inhaler Comprising a Dose Counter 2009, (WO2009022139).
39. Patel M., Pilcher J., Chan A., Perrin K., Black P., Beasley R. Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J. Allergy Clin. Immunol. 2012, 130:1420-1422.
40. Conner J.B., Buck P.O. Improving asthma management: the case for mandatory inclusion of dose counters on all rescue bronchodilators. J. Asthma 2013, 50:658-663.
41. Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur. Respir. J. 2007, 29:587-595.
42. Bodzenta-Lukaszyk A., Pulka G., Dymek A., Bumbacea D., McIver T., Schwab B., Mansikka H. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir. Med. 2011, 105:674-682.
43. Mahler D.A., D'Urzo A., Bateman E.D., Ozkan S.A., White T., Peckitt C., Lassen C., Kramer B. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
44. Tashkin D.P., Varghese S.T. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm. Pharmacol. Ther. 2011, 24:147-152.
45. Lechuga-Ballesteros D., Noga B., Vehring R., Cummings R.H., Dwivedi S.K. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med. Chem. 2011, 3:1703-1718.
46. Barnes P.J. Triple inhalers for obstructive airways disease: will they be useful?. Expert Rev. Respir. Med. 2011, 5:297-300.
47. Chatterjee A., Shah M., D'Souza A.O., Bechtel B., Crater G., Dalal A.A. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir. Res. 2012, 13:15.
48. Brambilla G., Howlett D., Johnson R., Lewis D.A. Metered-dose Inhaler and Method of Using the Same 2012, (WO 2012032010 A1).
49. Dohmeier D., Heyworth D., Wilde T. The application of a new high performance dual-layer coating to pressurized metered dose inhaler hardware. Respir Drug Deliv Eur 2009, 209-212.
50. Fradley G., Hodson D. Optimization of fluid flow in pMDI valves. Respiratory, Drug Delivery 2008, 329-332.
51. Rogueda P.G.A., Price R., Smith T., Young P.M., Traini D. Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. J. Colloid Interface Sci. 2011, 361:649-655.
52. J.G. Weers, E.G. Schutt, L.A. Dellamary, T.E. Tarara, A. Kabalnov, Stabilized preparations for use in metered dose inhalers. US Patent 6,309,623., (2001).
53. Vehring R., Lechuga-Ballesteros D., Joshi V., Noga B., Dwivedi S.K. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012, 28:15015-15023.
54. Miravitlles M., Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013, 188:1052-1057.
55. Hudson R., Blair B.O. Inhaled antibiotics for gram-negative respiratory infections. Future Med. Chem. 2011, 3:1663-1677.
56. Stein S.W., Forsyth B.R., Stefely J.S., Christensen J.D., Alband T.D., Jinks P.A. Expanding the dosing range of metered dose inhalers through formulation and hardware optimization. Respiratory, Drug Delivery 2004, 125-134.
57. Alston W., Clark A.R., Schuler C., Walsh K.R. Increased Dosage Metered Dose Inhaler 2004, (PCT/US2003/034473).
58. Dellamary L.A., Tarara T.E., Kabalnov A., Weers J.G., Schutt E.G. Stabilized Bioactive Preparations and Methods of Use 2002, (PCT/US1998/020613).
59. Zhu B., Traini D., Chan H.K., Young P.M. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Dev. Ind. Pharm. 2013, 39:1625-1637.
60. de Boer A.H., Chan H.K., Price R. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?. Adv. Drug Deliv. Rev. 2012, 64:257-274.
61. Coates M.S., Chan H.K., Fletcher D.F., Raper J.A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size. J. Pharm. Sci. 2006, 95:1382-1392.
62. Voss A., Finlay W.H. Deagglomeration of dry powder pharmaceutical aerosols. Int. J. Pharm. 2002, 248:39-50.
63. Tong Z.B., Zheng B., Yang R.Y., Yu A.B., Chan H.K. CFD-DEM investigation of the dispersion mechanisms in commercial dry powder inhalers. Powder Technol. 2013, 240:19-24.
64. Son Y.-J., Longest P.W., Tian G., Hindle M. Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulation. Eur. J. Pharm. Sci. 2013, 49:390-399.
65. Curtis R.M., Donovan M.J., Smyth H. Inhaler to Deliver Substances for Prophylaxis or Prevention of Disease or Injury Caused by the Chemical Agents 2013, (US2013/0213397 A1).
66. Ehtezazi T., Allanson D.R., Jenkinson I.D., Shrubb I., O'Callaghan C. Investigating improving powder deagglomeration via dry powder inhalers at a low inspiratory flow rate by employing add-on spacers. J. Pharm. Sci. 2008, 97:5212-5221.
67. Coates M.S., Fletcher D.F., Chan H.K., Raper J.A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J. Pharm. Sci. 2004, 93:2863-2876.
68. Zhou Q.T., Tong Z., Tang P., Citterio M., Yang R., Chan H.K. Effect of device design on the aerosolization of a carrier-based dry powder inhaler-a case study on Aerolizer Foradile. AAPS J. 2013, 15:511-522.
69. Longest P.W., Son Y.J., Holbrook L., Hindle M. Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols. Pharm. Res. 2013, 30:1608-1627.
70. Harrison L.I., Novak C.C., Needham M.J., Ratner P. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:245-252.
71. Selvam P., McNair D., Truman R., Smyth H.D.C. A novel dry powder inhaler: effect of device design on dispersion performance. Int. J. Pharm. 2010, 401:1-6.
72. Friebel C., Stolte S., Steckel H., Solomon I. Performance of a new single-use disposable dry powder inhaler prototype. Respiratory, Drug Delivery 2010, 517-522.
73. Wagenseil L., Menge A.K., Solomon I., Steckel H. Optimization and performance of the ResQhaler - a single-use disposable dry powder inhaler. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:A240.
74. Zhang X., Ma Y., Zhang L., Zhu J., Jin F. The development of a novel dry powder inhaler. Int. J. Pharm. 2012, 431:45-52.
75. Corcoran T.E., Venkataramanan R., Hoffman R.M., George M.P., Petrov A., Richards T., Zhang S., Choi J., Gao Y.Y., Oakum C.D., Cook R.O., Donahoe M. Systemic delivery of atropine sulfate by the MicroDose dry-powder inhaler. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:46-55.
76. Rabinowitz J.D., Wensley M., Lloyd P., Myers D., Shen W., Lu A., Hodges C., Hale R., Mufson D., Zaffaroni A. Fast onset medications through thermally generated aerosols. J. Pharmacol. Exp. Ther. 2004, 309:769-775.
77. Dinh K., Myers D.J., Glazer M., Shmidt T., Devereaux C., Simis K., Noymer P.D., He M., Choosakul C., Chen Q., Cassella J.V. In vitro aerosol characterization of Staccato® Loxapine. Int. J. Pharm. 2011, 403:101-108.
78. Rabinowitz J.D., Lloyd P.M., Munzar P., Myers D.J., Cross S., Damani R., Quintana R., Spyker D.A., Soni P., Cassella J.V. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J. Pharm. Sci. 2006, 95:2438-2451.
79. Borgstrom L., Olsson B., Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol Med. 2006, 19:473-483.
80. Tang P., Chan H.K., Rajbhandari D., Phipps P. Method to introduce mannitol powder to intubated patients to improve sputum clearance. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:1-9.
81. Chan H.-K., Rajbhandari D., Tang P., Brannan J.D., Phipps P. Safety of administering dry powder mannitol to stimulate sputum clearance in intubated intensive care patients with sputum retention: a pilot study. Am. J. Respir. Crit. Care Med. 2012, 185:A6809.
82. Wong W., Fletcher D.F., Traini D., Chan H.K., Young P.M. The use of computational approaches in inhaler development. Adv. Drug Deliv. Rev. 2012, 64:312-322.
83. Ruzycki C.A., Javaheri E., Finlay W.H. The use of computational fluid dynamics in inhaler design. Expert Opin. Drug Deliv. 2013, 10:307-323.
84. Kleinstreuer C., Shi H.W., Zhang Z. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology. J. Aerosol Med. 2007, 20:294-309.
85. Longest P.W., Hindle M. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:99-112.
86. Arulmuthu E.R., Williams D.J., Baldascini H., Versteeg H.K., Hoare M. Studies on aerosol delivery of plasmid DNA using a mesh nebulizer. Biotechnol. Bioeng. 2007, 98:939-955.
87. Shen S.-C., Wang Y.-J., Chen Y.-Y. Design and fabrication of medical micro-nebulizer. Sensors Actuators A Phys. 2008, 144:135-143.
88. Coates M.S., Chan H.K., Fletcher D.F., Raper J.A. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm. Res. 2005, 22:1445-1453.
89. Coates M.S., Chan H.-K., Fletcher D.F., Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm. Res. 2007, 24:1450-1456.
90. Coates M.S., Fletcher D.F., Chan H.K., Raper J.A. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm. Res. 2005, 22:923-932.
91. de Boer A.H., Hagedoorn P., Woolhouse R., Wynn E. Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer disposable high-dose dry powder inhaler. J. Pharm. Pharmacol. 2012, 64:1316-1325.
92. Jiang L.Q., Tang Y., Zhang H.J., Lu X.F., Chen X.J., Zhu J.B. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:265-279.
93. Donovan M.J., Kim S.H., Raman V., Smyth H.D. Dry powder inhaler device influence on carrier particle performance. J. Pharm. Sci. 2012, 101:1097-1107.
94. Shur J., Lee S., Adams W., Lionberger R., Tibbatts J., Price R. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS J. 2012, 14:667-676.
95. Tong Z.B., Yang R.Y., Chu K.W., Yu A.B., Adi S., Chan H.K. Numerical study of the effects of particle size and polydispersity on the agglomerate dispersion in a cyclonic flow. Chem. Eng. J. 2010, 164:432-441.
96. Tong Z.B., Adi S., Yang R.Y., Chan H.K., Yu A.B. Numerical investigation of the de-agglomeration mechanisms of fine powders on mechanical impaction. J. Aerosol Sci. 2011, 42:811-819.
97. Irene P., Gaetano B. Effect of the inhalation volume on drug delivery performance of NEXThaler®, in: Respiratory Drug Delivery Europe 2013, 273-278.
98. Voshaar T., Spinola M., Linnane P., Campanini A., Lock D., Lafratta A., Scuri M., Ronca B., Melani A. Comparing usability of NEXThaler® with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients. J. Aerosol Med. Pulm. Drug Deliv. 2013, (Ahead of print). 10.1089/jamp.2013.1086.
99. Blau H., Mussaffi H., Zahav M.M., Prais D., Livne M., Czitron B.M., Cohen H.A. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007, 33:491-495.
100. Cohen H.A., Cohen Z., Pomeranz A.S., Czitron B., Kahan E. Bacterial contamination of spacer devices used by asthmatic children. J. Asthma 2005, 42:169-172.
101. De Vries T.W., Rienstra S.R., Van Der Vorm E.R. Bacterial contamination of inhalation chambers: results of a pilot study. J. Aerosol Med. 2004, 17:354-356.
102. Mabbott F.A., Mullen A.B., Smith A., Smith G., Boyter A.C. Qualitative analysis of microbial contamination of inhalers. J. Hosp. Infect. 2011, 77:277-278.
103. de Boer A.H., Hagedoorn P., Westerman E.M., Le Brun P.P.H., Heijerman H.G.M., Frijlink H.W. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur. J. Pharm. Sci. 2006, 28:171-178.
104. Nardell E.A. Inhaled colistin: a novel approach for reducing drug-resistant TB transmission. 17th Annual Conference of the International Union Against Tuberculosis and Lung Disease - North American Region, Vancouver, BC, Canada 2013.
105. Zhou Q., Morton D. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv. Drug Deliv. Rev. 2012, 64:275-284.
106. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
107. Haynes A., Nakamura J., Heng C., Heuerding S., Thompson G., Malcolmson R. Aerosol performance of tobramycin inhalation powder. Respiratory, Drug Delivery 2010, 701-706.
108. Zhou Q., Morton D., Yu H.H., Jacob J., Wang J.P., Li J., Chan H.K. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J. Pharm. Sci. 2013, 102:3736-3747.
109. Zhou Q.T., Gengenbach T., Denman J.A., Yu H.H., Li J., Chan H.K. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014, 16:37-47.
110. Zhou Q.T., Qu L., Larson I., Stewart P.J., Morton D. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int. J. Pharm. 2010, 394:50-59.
111. Chan H.-K. Nanodrug particles and nanoformulations for drug delivery. Adv. Drug Deliv. Rev. 2011, 63:405.
112. Chan H.-K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
113. Zhang J., Wu L., Chan H.-K., Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:441-455.
114. Kwok P.C.L., Tunsirikongkon A., Glover W., Chan H.K. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm. Res. 2011, 28:788-796.
115. Heng D., Lee S.H., Ng W.K., Chan H.K., Kwek J.W., Tan R.B.H. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. Int. J. Pharm. 2013, 452:194-200.
116. Tajber L., Corrigan O.I., Healy A.M. Spray drying of budesonide, formoterol furnarate and their composites-II. Statistical factorial design and in vitro deposition properties. Int. J. Pharm. 2009, 367:86-96.
117. Kwok P.C.L., Chan H.K. Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols. Pharm. Res. 2008, 25:277-288.
118. Karner S., Anne Urbanetz N. The impact of electrostatic charge in pharmaceutical powders with specific focus on inhalation-powders. J. Aerosol Sci. 2011, 42:428-445.
119. Vladykina T.N., Deryagin B.V., Toporov Y.P. The effect of surface roughness on triboelectrification of insulators. Phys. Chem. Mech. Surf. 1985, 3:2817-2821.
120. Watanabe H., Ghadiri M., Matsuyama T., Ding Y.L., Pitt K.G., Maruyama H., Matsusaka S., Masuda H. Triboelectrification of pharmaceutical powders by particle impact. Int. J. Pharm. 2007, 334:149-155.
121. Carter P.A., Cassidy O.E., Rowley G., Merrifield D.R. Triboelectrification of fractionated crystalline and spray-dried lactose. Pharm. Pharmacol. Commun. 1998, 4:111-115.
122. Murtomaa M., Harjunen P., Mellin V., Lehto V.P., Laine E. Effect of amorphicity on the triboelectrification of lactose powder. J. Electrost. 2002, 56:103-110.
123. US Food and Drug Administration Medication guide. Foradil Certihaler (formoterol fumarate inhalation powder) http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088603.pdf.
124. UK Medicines and Healthcare Products Regulatory Agency Public Assessment Report. Pulmicort CFC-free Inhaler (Budesonide) 2008.
125. Zhou Q., Qu L., Gengenbach T., Larson I., Stewart P.J., Morton D. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech 2013, 14:38-44.
126. Zhou Q.T., Armstrong B., Larson I., Stewart P.J., Morton D. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur. J. Pharm. Sci. 2010, 40:412-421.
127. Chew N.Y.K., Shekunov B.Y., Tong H.H.Y., Chow A.H.L., Savage C., Wu J., Chan H.K. Effect of amino acids on the dispersion of disodium cromoglycate powders. J. Pharm. Sci. 2005, 94:2289-2300.
128. Paajanen M., Katainen J., Raula J., Kauppinen E.I., Lahtinen J. Direct evidence on reduced adhesion of Salbutamol sulphate particles due to l-leucine coating. Powder Technol. 2009, 192:6-11.
129. Sou T., Orlando L., McIntosh M.P., Kaminskas L.M., Morton D.A.V. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int. J. Pharm. 2011, 421:220-229.
130. Zhou Q., Denman J.A., Gengenbach T., Das S., Qu L., Zhang H.L., Larson I., Stewart P.J., Morton D.A.V. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J. Pharm. Sci. 2011, 100:3421-3430.
131. Behara S.B., Farkas D., Hindle M., Longest P.W. Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications. Pharm. Res. 2013, 1-13.
132. Strathmann S.C., Murphy M.A., Goeckner B.A., Carter P.W., Green J.-B.D. Forces between insulin microspheres and polymers surfaces for a dry powder inhaler. Int. J. Pharm. 2009, 372:147-153.
133. Lopez-Meseguer M., Berastegui C., Monforte V., Bravo C., Domingo E., Roman A. Inhaled Iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation. Transplant. Proc. 2013, 45:2347-2350.
134. Voswinckel R., Reichenberger F., Gall H., Schmehl T., Gessler T., Schermuly R.T., Grimminger F., Rubin L.J., Seeger W., Ghofrani H.A., Olschewski H. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm. Pharmacol. Ther. 2009, 22:50-56.
135. Phillips B.G., Bauman J.L., Schoen M.D., Hoon T.J., Schrader B.J., Rich S. Serum nifedipine concentrations and response of patients with pulmonary hypertension. Am. J. Cardiol. 1996, 77:996-999.
136. Malik A.S., Warshafsky S., Lehrman S. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Arch. Intern. Med. 1997, 157:621-625.
137. Moritz B.-B., Schweiger C., Schmehl T., Gessler T., Seeger W., Kissel T. Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. J. Control. Release 2012, 158:329-335.
138. Saigal A., Ng W.K., Tan R.B.H., Chan S.Y. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. Int. J. Pharm. 2013, 450:114-122.
139. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J. Cyst. Fibros. 2011, 10:54-61.
140. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur. J. Pharm. Biopharm. 2013, (e-pub). 10.1016/j.ejpb.2013.1010.1019.
141. Young P.M., Crapper J., Philips G., Sharma K., Chan H.-K., Traini D. Overcoming dose limitations using the Orbital® multi-breath dry powder inhaler. J. Aerosol Med. Pulm. Drug Deliv. 2013, (ahead of print). 10.1089/jamp.2013.1080.
142. Cipolla D., Chan H.-K. Inhaled antibiotics to treat lung infections. Pharm. Pat. Anal. 2013, 2:647-663.
143. Togami K., Chono S., Morimoto K. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:110-115.
144. Niederman M.S., Chastre J., Corkery K., Fink J.B., Luyt C.-E., García M.S. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012, 38:263-271.
145. Luyt C.-E., Clavel M., Guntupalli K., Johannigman J., Kennedy J.I., Wood C., Corkery K., Gribben D., Chastre J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit. Care 2009, 13.
146. Mombelli G., Coppens L., Thys J.P., Klastersky J. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob. Agents Chemother. 1981, 19:72-75.
147. Shaaltiel Y., Hanania U., Matiuhin Y., Fux L., Shulman A., Kizhner T. Dry Powder Formulation of DNase 1 2013, (WO2013114371 (A1)).
148. Kaare F. Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin 2008, (WO2008071197 (A1)).
149. Heng D., Lee S.H., Teo J., Ng W.K., Chan H.-K., Tan R.B.H. Synergistic combination dry powders for inhaled antimicrobial therapy. AIP Conf. Proc. 2013, 1542:113-116.
150. Zhou Q., Gengenbach T., Denman J.A., Yu H.H., Li J., Chan H.K. Inhalable powder formulations of combination antibiotics with enhanced antimicrobial activities, 2014, Respiratory Drug Delivery 2014. Fajardo, Puerto Rico, May 4-8, 2014.
151. Chan J.G.Y., Tyne A.S., Pang A., Chan H.-K., Young P.M., Britton W.J., Duke C.C., Traini D. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm. Res. 2013, (Published online 16 Nov 2013). 10.1007/s11095-013-1245-7.
152. Chan J.G.Y., Chan H.-K., Prestidge C.A., Denman J.A., Young P.M., Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur. J. Pharm. Biopharm. 2013, 83:285-292.
153. Schoubben A., Blasi P., Marenzoni M.L., Barberini L., Giovagnoli S., Cirotto C., Ricci M. Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization. Eur. J. Pharm. Biopharm. 2013, 83:388-395.
154. Moretton M.A., Chiappetta D.A., Andrade F., das Neves J., Ferreira D., Sarmento B., Sosnik A. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J. Biomed. Nanotechnol. 2013, 9:1076-1087.
155. Ikematsu H., Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev. Anti-Infect. Ther. 2011, 9:851-857.
156. Sunagawa S., Higa F., Cash H.L., Tateyama M., Uno T., Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respi. Viruses 2013, 7:1-3.
157. Kashiwagi S., Yoshida S., Yamaguchi H., Mitsui N., Tanigawa M., Shiosakai K., Yamanouchi N., Shiozawa T., Yamaguchi F. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J. Infect. Chemother. 2013, 19:223-232.
158. Kubo S., Kakuta M., Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn. J. Antibiot. 2010, 63:337-346.
159. Yamashita M., Tomozawa T., Kakuta M., et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
160. Kawai N., Ikematsu H., Iwaki N., et al. Clinical effectiveness of oseltamivir for influenza A (H1N1) virus with H274Y neuraminidase mutation. J. Infect. 2009, 59:207-212.
161. Itoh Y., Shinya K., Kiso M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
162. Kahan B.D. Cyclosporine. N. Engl. J. Med. 1989, 321:1725-1738.
163. Groves S., Galazka M., Johnson B., Corcoran T., Verceles A., Britt E., Todd N., Griffith B., Smaldone G.C., Iacono A. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:31-39.
164. Nieven R.W., Verret V., Raff H., Corcoran T., Dilly S.G. The challenges of developing an inhaled cyclosporine product for lung transplant patient. Respiratory Drug Delivery 2012, 51-60.
165. Behr J., Zimmermann G., Baumgartner R., et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:121-130.
166. Sato H., Ogawa K., Kojo Y., Kawabata Y., Mizumoto T., Yamada S., Onoue S. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy. Int. J. Pharm. 2013, 448:282-289.
167. Yamasaki K., Kwok P.C.L., Fukushige K., Prud'homme R.K., Chan H.-K. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int. J. Pharm. 2011, 420:34-42.
168. Wu X., Zhang W., Jr Hayes D., Mansour H.M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int. J. Nanomedicine 2013, 8:1269-1283.
169. Whitefield N.K., Martyn G., Dey F., Crew P. Immunosuppressant Microparticles Composition 2012, (WO2010130982 (A2)).
170. Willis L., Hayes D., Mansour H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012, 190:251-262.
171. Mohanka M., Khemasuwan D., Stoller J.K. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin. Biol. Ther. 2012, 12:685-700.
172. Hubbard R.C., Brantly M.L., Sellers S.E., et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin. Ann. Intern. Med. 1989, 111:206-212.
173. Brand P., Schulte M., Wencker M., Herpich C.H., Klein G., Hanna K., Meyer T. Lung deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiency. Eur. Respir. J. 2009, 34:354-360.
174. Geller D.E., Kesser K.C. The I-neb adaptive aerosol delivery system enhances delivery of a1-antitrypsin with controlled inhalation. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:S55-S59.
175. Tazawa R., Trapnell B.C., Inoue Y., Arai T., Takada T., Nasuhara Y., Hizawa N., Kasahara Y., Tatsumi K., Hojo M., Ishii H., Yokoba M., Tanaka N., Yamaguchi E., Eda R., Tsuchihashi Y., Morimoto K., Akira M., Terada M., Otsuka J., Ebina M., Kaneko C., Nukiwa T., Krischer J.P., Akazawa K., Nakata K. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 2010, 181:1345-1354.
176. Portal J.A.R., Becerra E.R., Garrido A.S. Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis. Arch. Bronconeumol. 2009, 45:150-152.
177. Venkateshiah S.B., Yan T.D., Bonfield T.L., Thomassen M.J., Meziane M., Czich C., Kavuru M.S. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006, 130:227-237.
178. Comparing efficacy and safety of inhaled SNG001 to placebo http://clinicaltrials.gov/ct2/show/NCT01126177.
179. http://www.synairgen.com/programmes/ifn-%DF-in-copd.aspx.
180. http://www.synairgen.com/programmes/ifn-%DF-in-severe-viral-lung-infection.aspx.
181. Rafii R., Juarez M.M., Albertson T.E., Chan A.L. A review of current and novel therapies for idiopathic pulmonary fibrosis. J. Thorac. Dis. 2013, 5:48-73.
182. King T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., Noble P.W., Sahn S.A., Szwarcberg J., Thomeer M., Valeyre D., du Bois R.M., Grp I.S. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374:222-228.
183. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011, 91:71-81.
184. Wallis R.S. Lack of a therapeutic role for interferon gamma in patients with tuberculosis. J. Infect. Dis. 2014, 209:627-U6628.
185. Condos R., Rom W.N., Schluger N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349:1513-1515.
186. Suarez-Mendez R., Garcia-Garcia I., Fernandez-Olivera N., Valdes-Quintana M., Milanes-Virelles M.T., Carbonell D., Machado-Molina D., Valenzuela-Silva C.M., Lopez-Saura P.A. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 2004, 4.
187. Koh W.J., Kwon O.J., Suh G.Y., Chung M.P., Kim H., Lee N.Y., Kim T.S., Lee K.S. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci. 2004, 19:167-171.
188. Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., Brauns C., Weiden M., Hoshino Y., Bateman E., Rom W.N. Immunomodulation with recombinant interferon-gamma 1b in pulmonary tuberculosis. PLoS One 2009, 4.
189. Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv. Drug Deliv. Rev. 2006, 58:1089-1105.
190. Huland E., Heinzer H., Huland H. Overview of interleukin-2 inhalation therapy. Cancer J. Sci. Am. 2000, 6:S104-S112.
191. Posch C., Weihsengruber F., Bartsch K., Feichtenschlager V., Sanlorenzo M., Vujic I., Monshi B., Ortiz-Urda S., Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br. J. Cancer 2014, 110:1427-1432. 10.1038/bjc.2014.62.
192. O'Byrne P.M. Role of monoclonal antibodies in the treatment of asthma. Can. Respir. J. 2013, 20:23-25.
193. Fahy J.V., Cockcroft D.W., Boulet L.P., Wong H.H., Deschesnes F., Davis E.E., Ruppel J., Su J.Q., Adelman D.C. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1999, 160:1023-1027.
194. O'Kane C., Bayliffe A., Serone A., Bareille P., Smith S., Hamid U., Brown V., Wright T., Chen Y., Wilson R., Elborn J.S., McAuley D.F. Tumour Necrosis Factor receptor 1 inhibition using a novel inhaled human antibody reduces inflammation in a human model of lung injury induced by inhaled lipopolysaccharide; a randomised placebo-controlled clinical trial. Thorax 2013, 68:A51.